Development and validation of a prognostic staging system for primary plasma cell leukemia.

原发性浆细胞白血病预后分期系统的建立与验证

阅读:21
作者:Tian Mengru, An Gang, Fu Weijun, Yan Wenqiang, Li Lu, Sun Chunyan, Li Zhenyu, Chen Lijuan, Liao Aijun, Gao Guangxun, Qin Xiaoqi, Li Mengyao, Li Chunrui, Xue Hua, Gao Li, Wang Yi, He Aili, Zhou Fan, Guo Dongmei, Dong Yujun, Fang Zhihong, Chu Xiaoxia, Mi Jianqing, Fu Chengcheng, Zeng Hui, Hou Shuling, Wang Xiaotao, Wang Hua, Wei Yongqiang, Liang Xinyue, Yi Xingcheng, Sun Yue, Qiu Lugui, Dai Yun, Jin Fengyan
BACKGROUND: The existing risk models for multiple myeloma (MM) are suboptimal for the stratification of patients with primary plasma cell leukemia (pPCL), a rare and peculiar MM. In this study, we aimed to develop a staging system for pPCL defined as the presence of ≥ 5% circulating plasma cells (CPC) according to the new diagnostic criteria, utilizing one of the largest series of patients with pPCL. METHODS: This multicenter retrospective study included 340 patients with pPCL (the training cohort) from 25 centers nationwide in China. The prognostic impact of baseline characteristics and cytogenetic abnormalities was evaluated. Univariate and multivariate analyses were conducted to identify variables predicting overall survival (OS) to develop a staging system. Its performance was then validated in an independent cohort (n = 80). Genome-wide DNA and RNA sequencing were performed to explore the molecular basis for inter-stage clinical heterogeneity. RESULTS: Del(17p), t(4;14), and t(14;16), but not 1q+, were verified as high-risk cytogenetic abnormalities (HRCAs) of pPCL. HRCA, elevated LDH, and thrombocytopenia had the highest impact on OS and were used to create a simple algorithm, stratifying patients with pPCL into stages I, II, and III, with median OS of 54.1, 24.0, and 5.4 months (II vs. I: HR, 1.986; 95% CI, 1.034-3.814; P = 0.0394; III vs. II: HR, 3.206; 95% CI, 1.757-5.852; P = 0.0001) in the training cohort and 62.1, 31.6, and 21.8 months (II vs. I: HR, 2.013; 95% CI, 0.954-4.251; P = 0.0664; III vs. II: HR, 2.694; 95% CI, 1.136-6.392; P = 0.0245) in the independent validation cohort. The accuracy (c-index 0.711) was higher than other models. Moreover, patients with different stages had highly diverse genomic and transcriptomic aberrations. CONCLUSIONS: We propose a pPCL-specific staging system based on LDH, thrombocytopenia, and cytogenetic abnormalities, which warrants further validation, particularly in a prospective setting.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。